**Supplementary Table 2. Scenario analysis with 65-79 and 70-79 age cohorts. Results per million people. ICER=Incremental Cost-Effectiveness Ratio; I- HNS=Italian National Health Service; HZ=Herpes Zoster; PHN = Post Herpetic Neuralgia.**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | | Vaccination policy | Non-Vaccination policy | Difference | ICER I-NHS | ICER Societal |
| Age 65-79 | | | | | | | |
| Costs | | Costs – Societal perspective | €95,451,359 | €85,892,387 | €9,558,973 |  |  |
| Costs –I-NHS perspective | €94,991,843 | €85,373,545 | €9,618,298 |  |  |
| Effectiveness | | QALY | 8,485,593 | 8,484,610 | 984 | €9,779 | €9,719 |
| HZ cases | 205,551 | 213,757 | 8,206 | €1,172 | €1,165 |
| PHN cases (3 months) | 19.488 | 21.376 | 1.888 | €5,094 | €5,063 |
| Age 70-79 | | | | | | | |
| Costs | | Costs – Societal perspective | €90,649,904 | €81,658,583 | €8,991,321 |  |  |
| Costs – I-NHS perspective | €90,649,904 | €81,658,583 | €8,991,321 |  |  |
| Effectiveness | | QALY | 7,510,577 | 7,509,548 | 1,030 | €8,729 | €8,729 |
| HZ cases | 180.329 | 187.258 | 6.930 | €1,297 | €1,297 |
| PHN cases (3 months) | 17,374 | 19,332 | 1,958 | €4,592 | €4,592 |